Success Metrics

Completion Rate

0%(0/2)

Active Trials

0(0%)

Terminated

2(100%)

Phase Distribution

Ph phase_1

100%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution2 total trials

Phase 1Safety & dosage

2(100.0%)

Highest Phase Reached

Phase 1

Trial Status & Enrollment

Completion Rate

0.0%

0 of 2 finished

Non-Completion Rate

100.0%

2 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Terminated(2)

Detailed Status

Terminated2

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

0.0%

Most Advanced

Phase 1

Trials by Phase

Phase 12 (100.0%)

Trials by Status

terminated2100%

Recent Activity

0 active trials

Showing 2 of 2

terminatedphase_1

Study to Assess AFM24 in Combination With Atezolizumab in Selected Advanced/Metastatic EGFR-expressing Cancers

NCT05109442

terminatedphase_1

Safety, Tolerability, and Anti-Tumor Activity of AFM24 in Combination With SNK01 in Subjects With Advanced/Metastatic EGFR-Expressing Cancers

NCT05099549

Clinical Trials (2)

Showing 2 of 2 trials

NCT05109442Phase 1

Study to Assess AFM24 in Combination With Atezolizumab in Selected Advanced/Metastatic EGFR-expressing Cancers

Terminated

NCT05099549Phase 1

Safety, Tolerability, and Anti-Tumor Activity of AFM24 in Combination With SNK01 in Subjects With Advanced/Metastatic EGFR-Expressing Cancers

Terminated

All 2 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 2